West Pharmaceutical (WST) Enters Drug Containment Tech. Evaluation Agreement with Amgen (AMGN)
Tweet
Share
E-mailGet Alerts WST Hot Sheet
Join SI Premium – FREE
West Pharmaceutical Services, Inc. (NYSE: WST), announced an agreement with Amgen Inc. (Nasdaq: AMGN), a biotechnology pioneer and one of the world's leading independent biotechnology companies, to evaluate Daikyo Crystal Zenith technologies for drug containment.
These technologies were developed over many years by West's partner, Daikyo Seiko, Ltd., and are based on a polymeric container, utilizing elastomeric components with Flurotec barrier film, and provided in a sterile, validated, ready-to-fill format.
These technologies were developed over many years by West's partner, Daikyo Seiko, Ltd., and are based on a polymeric container, utilizing elastomeric components with Flurotec barrier film, and provided in a sterile, validated, ready-to-fill format.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FTC files amicus brief challenging Amgen's Enbrel patent acquisition
- Solowin Holdings marks 10 years, expands into stablecoins and AI
- Home Depot expands executive roles, grants $500K in restricted stock
Create E-mail Alert Related Categories
Corporate NewsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
